ArticleJournal of the National Cancer Institute2019
Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- How effective is acupuncture in treating hot flashes in breast cancer patients? A systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Pooled it
- The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.Breast (Edinburgh, Scotland) · 2022Pooled it
- Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Trial
- Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.Journal of the National Cancer Institute · 2025Trial
- Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.Breast cancer research and treatment · 2024Trial
- Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.Breast cancer research and treatment · 2023Trial
- Trial
- Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ.JAMA network open · 2026Article
- Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.Breast cancer research and treatment · 2026Article
- Mortality prediction with adjuvant tamoxifen in breast cancer: Machine learning-integrated explainable artificial intelligence and Bayesian model results.ADMET & DMPK · 2026Article
- Improving treatment education in Black and South Asian women.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial.JCO oncology advances · 2025Article
- Prevalence and predictive testing preferences for breast cancer treatment side effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Barriers to endocrine therapy adherence: perspectives of Black breast cancer survivors and their providers.Journal of cancer survivorship : research and practice · 2025Article
- Rationale and design of the IMProving Adherence to medications for breast Cancer and cardiovascular disease equiTably (IMPACT) randomized clinical trial.Contemporary clinical trials · 2025Article
- Unmet needs among long-term breast cancer survivors.Cancer causes & control : CCC · 2025Article
- Extended endocrine therapy use and decision making after breast cancer diagnosis.Journal of the National Cancer Institute · 2025Article
- Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.Journal of cancer survivorship : research and practice · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDifferential use of endocrine therapy (ET) by race may contribute to breast cancer outcome disparities, but racial differences in ET behaviors are poorly understood.
methodsWomen aged 20-74 years with a first primary, stage I-III, hormone receptor-positive (HR+) breast cancer were included. At 2 years postdiagnosis, we assessed nonadherence, defined as not taking ET every day or missing more than two pills in the past 14 days, discontinuation, and a composite measure of underuse, defined as either missing pills or discontinuing completely. Using logistic regression, we evaluated the relationship between race and nonadherence, discontinuation, and overall underuse in unadjusted, clinically adjusted, and socioeconomically adjusted models.
resultsA total of 1280 women were included; 43.2% self-identified as black. Compared to white women, black women more often reported nonadherence (13.7% vs 5.2%) but not discontinuation (10.0% vs 10.7%). Black women also more often reported the following: hot flashes, night sweats, breast sensitivity, and joint pain; believing that their recurrence risk would not change if they stopped ET; forgetting to take ET; and cost-related barriers. In multivariable analysis, black race remained statistically significantly associated with nonadherence after adjusting for clinical characteristics (adjusted odds ratio = 2.72, 95% confidence interval = 1.75 to 4.24) and after adding socioeconomic to clinical characteristics (adjusted odds ratio = 2.44, 95% confidence interval = 1.50 to 3.97) but was not independently associated with discontinuation after adjustment. Low recurrence risk perception and lack of a shared decision making were strongly predictive of ET underuse across races.
conclusionsOur results highlight important racial differences in ET-adherence behaviors, perceptions of benefits/harms, and shared decision making that may be targeted with culturally tailored interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.